Kiniksa Pharmaceuticals International, plc
Rank #28HypergrowthKNSA · Nasdaq · Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) — Rank #28 by gross profitability (GP/assets 0.73) · ROE 9.7% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001730430 · all metrics point-in-time as of the filing date.
About
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Show moreShow less
The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.
Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- kiniksa.com
Segments
A revenue-by-segment breakdown is not available for KNSA. This is expected for a single-reportable-segment filer with no product/service revenue disaggregation, or for a company whose filings predate SEC’s XBRL viewer.